免疫组织化学检测的CD44表达在外阴癌患者中的预后价值。

Prognostic value of immunohistochemically detected CD44 expression in patients with carcinoma of the vulva.

作者信息

Tempfer C, Gitsch G, Haeusler G, Reinthaller A, Koelbl H, Kainz C

机构信息

Department of Gynecology and Obstatrics, University of Vienna, Austria.

出版信息

Cancer. 1996 Jul 15;78(2):273-7. doi: 10.1002/(SICI)1097-0142(19960715)78:2<273::AID-CNCR13>3.0.CO;2-T.

DOI:10.1002/(SICI)1097-0142(19960715)78:2<273::AID-CNCR13>3.0.CO;2-T

PMID:8674003

Abstract

BACKGROUND

Overexpression of alternatively spliced CD44 isoforms has been reported to correlate with poor prognosis in several human malignancies. To the authors' knowledge, there are no studies concerning the prognostic value of CD44 isoform overexpression in patients with squamous cell carcinoma of the vulva.

METHODS

Thirty cases of squamous cell carcinoma of the vulva with International Federation of Gynecology and Obstetrics Stage I to III were examined immunohistochemically for overexpression of CD44 isoforms. We used 3 different variant exon sequence-specific murine monoclonal antibodies to CD44 isoforms containing variant exons v5, v6, and v7 to -8, respectively. The correlation of CD44 overexpression with clinical stage, histologic grade, and disease free and overall survival was investigated.

RESULTS

CD44 isoforms CD44v5, CD44v6, and CD44v7-8 were detected in 83% (25/30), 63% (19/30), and 27% (8/30) of the tumor samples, respectively. Patients with tumors overexpressing CD44v6 showed a significantly shorter relapse free (log rank test, P = 0.002) and overall survival (log rank test, P = 0.003) compared with patients with tumors lacking CD44v6 overexpression. Expression of CD44v5 and CD44v7 to 8 had no impact on patients' survival. Clinical stage and histologic grade did not correlate with CD44 overexpression.

CONCLUSIONS

Immunohistochemically detected overexpression of CD44 isoforms containing variant exon v6 is correlated with a poor relapse free and overall survival in patients with carcinoma of the vulva.

摘要

背景

据报道，选择性剪接的CD44亚型的过表达与多种人类恶性肿瘤的不良预后相关。据作者所知，目前尚无关于CD44亚型过表达在外阴鳞状细胞癌患者中的预后价值的研究。

方法

对30例国际妇产科联盟分期为I至III期的外阴鳞状细胞癌病例进行免疫组织化学检查，以检测CD44亚型的过表达情况。我们分别使用3种不同的针对包含可变外显子v5、v6以及v7至v8的CD44亚型的可变外显子序列特异性鼠单克隆抗体。研究了CD44过表达与临床分期、组织学分级、无病生存期和总生存期的相关性。

结果

肿瘤样本中分别有83%（25/30）、63%（19/30）和27%（8/30）检测到CD44亚型CD44v5、CD44v6和CD44v7 - 8。与未过表达CD44v6的肿瘤患者相比，过表达CD44v6的肿瘤患者的无复发生存期（对数秩检验，P = 0.0）和总生存期（对数秩检验，P = 0.003）显著缩短。CD44v5和CD44v7至v8的表达对患者生存无影响。临床分期和组织学分级与CD44过表达无关。